These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370 [TBL] [Abstract][Full Text] [Related]
11. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis. Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884 [TBL] [Abstract][Full Text] [Related]
13. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology]. Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393 [TBL] [Abstract][Full Text] [Related]
14. [Cutaneous side effects of EGFR inhibitors--appearance and management]. Wollenberg A; Kroth J; Hauschild A; Dirschka T Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous drug eruptions associated with the use of new oncological drugs. Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863 [TBL] [Abstract][Full Text] [Related]
16. [Cutaneous side effects of sorafenib and sunitinib]. Autier J; Mateus C; Wechsler J; Spatz A; Robert C Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102 [No Abstract] [Full Text] [Related]
17. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Daud A; Tsai K Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719 [TBL] [Abstract][Full Text] [Related]